The COVID-19 Winners: Vaccine stocks
It’s missing CureVac, a German mRNA vaccine maker. (It’s the German Biotech that allegedly Trump had sought to buy exclusive US rights to potential vaccines and to reallocate to US.)
CureVac had their IPO in 14 August 2020 (offering at $16 per share, began trading at $44 per share).
So in this shorter time period between 14/Aug./20 - 31/Mar./21 (5 months less on the used time period) it had a +107.9% return and $1,000 have become $2,078.64.
CureVac have GlaxoSmithKline (GSK) and the German government as shareholders (private offering).